<?xml version='1.0' encoding='utf-8'?>
<document id="24998012"><sentence text="Pharmacokinetic interaction between rosuvastatin and telmisartan in healthy Korean male volunteers: a randomized, open-label, two-period, crossover, multiple-dose study."><entity charOffset="36-48" id="DDI-PubMed.24998012.s1.e0" text="rosuvastatin" /><entity charOffset="53-64" id="DDI-PubMed.24998012.s1.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.24998012.s1.e0" e2="DDI-PubMed.24998012.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24998012.s1.e0" e2="DDI-PubMed.24998012.s1.e1" /></sentence><sentence text="Rosuvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, and telmisartan, an angiotensin receptor blocker, are commonly prescribed in combination for the treatment of dyslipidemia accompanied by hypertension"><entity charOffset="0-12" id="DDI-PubMed.24998012.s2.e0" text="Rosuvastatin" /><entity charOffset="89-100" id="DDI-PubMed.24998012.s2.e1" text="telmisartan" /><entity charOffset="105-116" id="DDI-PubMed.24998012.s2.e2" text="angiotensin" /><pair ddi="false" e1="DDI-PubMed.24998012.s2.e0" e2="DDI-PubMed.24998012.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24998012.s2.e0" e2="DDI-PubMed.24998012.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24998012.s2.e0" e2="DDI-PubMed.24998012.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24998012.s2.e1" e2="DDI-PubMed.24998012.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24998012.s2.e1" e2="DDI-PubMed.24998012.s2.e2" /></sentence><sentence text=" However, the nature of the pharmacokinetic interaction between the 2 drugs is not clearly understood" /><sentence text=" The goal of the present study was to investigate the pharmacokinetic drug-drug interaction between rosuvastatin and telmisartan in a healthy Korean population"><entity charOffset="100-112" id="DDI-PubMed.24998012.s4.e0" text="rosuvastatin" /><entity charOffset="117-128" id="DDI-PubMed.24998012.s4.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.24998012.s4.e0" e2="DDI-PubMed.24998012.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24998012.s4.e0" e2="DDI-PubMed.24998012.s4.e1" /></sentence><sentence text="" /><sentence text="This was a randomized, 2-part, open-label, 2-period, crossover, multiple-dose study, with each part composed of different subjects between the ages of 20 and 55 years" /><sentence text=" In part 1, each subject received rosuvastatin 20 mg with and without telmisartan 80 mg once daily for 6 consecutive days"><entity charOffset="34-46" id="DDI-PubMed.24998012.s7.e0" text="rosuvastatin" /></sentence><sentence text=" In part 2, each subject received telmisartan 80 mg with and without rosuvastatin 20 mg once daily for 6 consecutive days"><entity charOffset="34-45" id="DDI-PubMed.24998012.s8.e0" text="telmisartan" /><entity charOffset="69-81" id="DDI-PubMed.24998012.s8.e1" text="rosuvastatin" /><pair ddi="false" e1="DDI-PubMed.24998012.s8.e0" e2="DDI-PubMed.24998012.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24998012.s8.e0" e2="DDI-PubMed.24998012.s8.e1" /></sentence><sentence text=" In both parts, there was a 16-day washout period between mono- and coadministration" /><sentence text=" Blood samples were collected up to 72 hours after the last dose" /><sentence text=" Adverse events (AEs) were evaluated through interviews and physical examinations" /><sentence text="" /><sentence text="In part 1, the 90% CIs of the geometric mean ratios for the primary pharmacokinetic parameters for coadministration of the 2 drugs to monoadministration of each drug were 1" /><sentence text="0736-1" /><sentence text="2932 for AUCτ and 1" /><sentence text="7442-2" /><sentence text="3229 for Cmax,ss for rosuvastatin and 0"><entity charOffset="21-33" id="DDI-PubMed.24998012.s17.e0" text="rosuvastatin" /></sentence><sentence text="9942-1" /><sentence text="1594 for AUCτ and 1" /><sentence text="3593-1" /><sentence text="7169 for Cmax,ss for N-desmethyl rosuvastatin, whereas in part 2, the CIs were 1"><entity charOffset="21-45" id="DDI-PubMed.24998012.s21.e0" text="N-desmethyl rosuvastatin" /></sentence><sentence text="0834-1" /><sentence text="2672 for AUCτ and 1" /><sentence text="1534-1" /><sentence text="5803 for Cmax,ss for telmisartan"><entity charOffset="21-32" id="DDI-PubMed.24998012.s25.e0" text="telmisartan" /></sentence><sentence text=" The most frequently noted AE was cough in part 1, which occurred in 2 subjects receiving the combination therapy, and oropharyngeal pain in part 2, which occurred in 3 subjects receiving the combination therapy" /><sentence text=" All reported AEs were mild or moderate, and there was no significant difference in incidence between the treatments" /><sentence text="" /><sentence text="These findings demonstrated that rosuvastatin and telmisartan mutually affected each other's pharmacokinetics, suggesting a possibility of drug-drug interaction"><entity charOffset="33-45" id="DDI-PubMed.24998012.s29.e0" text="rosuvastatin" /><entity charOffset="50-61" id="DDI-PubMed.24998012.s29.e1" text="telmisartan" /><pair ddi="false" e1="DDI-PubMed.24998012.s29.e0" e2="DDI-PubMed.24998012.s29.e0" /><pair ddi="false" e1="DDI-PubMed.24998012.s29.e0" e2="DDI-PubMed.24998012.s29.e1" /></sentence><sentence text=" However, based on dose-response characteristics of the 2 drugs and previous results from other interaction studies, the degree of drug interaction observed in this study was not regarded as clinically significant" /><sentence text=" All treatments were well tolerated, with no serious AEs observed" /><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT01992601" /><sentence text="" /></document>